SonoScape Flagship 4-LED equipped FHD Endoscopy System

Demostrated at Conference "Endoscopy on Air"

SonoScape notes on June 5, 2020, “Endoscopy on Air”, an on-line international GI endoscopy conference led by faculties from 23 cities worldwide has attracted more than 20,000 viewers. The event touched upon the full spectrum of diagnostic and therapeutic endoscopy through the live streaming of more than 50 cases. SonoScape participated in the event as the silver sponsor.

SonoScape started as one of the top ultrasound manufacturers globally, but it refused to be limited by its own shadow. Since the establishment of its endoscopy division in 2012, the company keeps up its incredibly fast pace in product development. The latest and much-praised HD-550, a Full-High-Definition video endoscopy system is now paired with a 4-LED light source, setting up a major milestone on SonoScape’s product roadmap. The system delivers a noticeably boosted performance. At every turn, the added brightness allows even more image details, under both White Light or chromoendoscopy SFI/VIST modes.

The new SonoScape Flagship 4-LED equipped FHD Endoscopy System was used in two live demos of the marathonlike endoscopy Live conference. Cases were performed respectively by Prof. Zhou Ping-Hong, a global elite doctor in Shanghai Zhongshan Hospital of Fudan University in China, and Dr. Roberta Maselli in Humanitas Hospital Milan, Italy.

“This is one of the best endoscopic images I have ever seen.” Dr. Maselli commented during her procedure: “Plus, the aspect of extensive vascular ectasias in the stomach is clearly revealed, as it becomes much more noticeable under the SFI mode.”

Facing a transformational time for industry conferences, SonoScape’s new flagship system, HD-550 with 4-LED light source, received high appraisals from the endoscopist community, both online and off.

SourceSonoScape

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version